OncoSec Medical immunotherapy helps reduce tumors in mice

|About: OncoSec Medical Incorporated (ONCS)|By:, SA News Editor

OncoSec Medical (ONCS.OB) says that combining ImmunoPulse DNA-based immunotherapy with anti-CTLA4 and anti-PD1 antibodies was effective in reducing tumors in a trial of 40 mice.

While the mice were treated with ImmunoPulse alone, or in combination with anti-CTLA4, anti-PD1 or both, there was 100% regression of treated lesions in all of the animals, with none dying due to toxicity.

OncoSec now intends to test various approaches in more aggressive melanoma models with a view to eventually carrying out human trials. (PR)